Considering this biphasic weight pattern in PD, the dual action of GLP-1 RAs, reducing insulin resistance while inducing weight loss, raises important considerations regarding their long-term metabolic effects in PD patients with varying phenotypes and nutritional profiles. Here, GLP1R is linked to Parkinson disease.